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Abstract
Background: Despite the increase in the number of clinical trials in low and middle income countries (LMICs),
there has been little serious discussion of whether First in Human (FIH; phase 0 and phase 1) clinical trials should
be conducted in LMICs, and if so, under what conditions. Based on our own experience, studies and consultations,
this paper aims to stimulate debate on our contention that for products meant primarily for conditions most
prevalent in LMICs, FIH trials should preferably be done first in those countries.
Discussion: There are scientific and pragmatic arguments that support conducting FIH trials in LMIC. Furthermore,
the changing product-development and regulatory landscape, and the likelihood of secondary benefits such as
capacity building for innovation and for research ethics support our argument. These arguments take into account
the critical importance of protecting human subjects of research while developing capacity to undertake FIH trials.
Summary: While FIH trials have historically not been conducted in LMICs, the situation in some of these countries
has changed. Hence, we have argued that FIH should be conducted in LMICs for products meant primarily for
conditions that are most prevalent in those contexts; provided the necessary protections for human subjects are
sufficient.
Background
Despite the sustained proliferation of clinical trials in
low and middle income countries (LMICs), [1] there has
been little examination of whether First in Human (FIH;
phase 0 and phase 1) clinical trials should be conducted
in LMICs, and if so, under what conditions. Most of the
discussion has focused on later phases of clinical trials.
The purpose of this paper is to stimulate debate on the
merits of FIH trials in LMICs: the default option should
be to do the trials where the relevant health conditions
present the greatest public health challenge, if, and only
if, the necessary capacities exist for participant safety
and scientific rigor. We argue, further, that the default
presumptions against performing FIH trials in LMICs
may be quietly impeding progress in the evolution of
the very capacities that these trials require.
Interest in FIH clinical trials has grown recently, in
part because of the disastrous experience of the phase I
clinical trial of the superagonistic anti-CD28 antibody
TGN1412 in the United Kingdom. The drug was devel-
oped with the intention to stimulate a specific kind of
T-cell while at the same time controlling the production
of other T-cells in order to suppress the immune sys-
tem. In this trial, six healthy volunteers developed a
cytokine release syndrome with multi-organ failure and
required intensive care [2,3]. There were mistakes made
in that case, and some of the key lessons have been
translated into more stringent rules and new guidelines
[3-5].
FIH trials are studies where an investigational medical
product (drug, vaccine, medical device, etc), previously
developed and assessed through in vitro or animal test-
ing, or through mathematical modeling, is tested on
human subjects for the first time [4,5]. In drug develop-
ment, such trials involve administering single low, sub-
therapeutic doses to a small number of healthy volun-
teers (10 to 15) to gather preliminary data on the
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These trials help researchers identify the drug candidate
with the best pharmacological parameters to take for-
ward for further development and which one to leave
out. Traditionally, these early phase trials have been
conducted in high income countries (HICs). Until
recently they were very rarely, if ever, performed in
LMICs even for conditions that are most prevalent in
those countries. Why haven’t FIH trials been more com-
mon in LMICs?
The main historical reasons have been the lack of
research and clinical infrastructure, inadequate institu-
tional capacity, and weak regulatory agencies in many
LMICs. This has made it difficult for product develo-
pers, usually large multinational pharmaceutical compa-
nies, and regulatory agencies in developed countries to
achieve the necessary standards of safety for trial partici-
pants, and clinical and scientific rigor in LMICs [6].
LMICs themselves have often relied on product registra-
tion processes by regulatory authorities in developed
countries [6]. At the same time, regulatory authorities in
developed countries often lack knowledge of the dis-
eases, including many of the so-called Neglected Tropi-
cal Diseases (NTDs), and the local conditions most
prevalent in LMICs, making it possible that they will
make judgments based on inappropriate risk-benefit
assessments [7], potentially to the detriment of popula-
tions in LMICs. Another reason is that Western compa-
nies, which currently develop most new and innovative
products, have considered it risky to conduct FIH trials
in LMICs for various reasons, including the inability to
discriminate adverse events (AEs) caused by the investi-
gational product from the generally much higher fre-
quency of all types of undiagnosed symptoms and
untreated morbidities, the cultural obstacles to under-
taking autopsies and the fear that they may be perceived
to be exploiting vulnerable persons in these countries
[8]. The fact that so few companies do FIH trials in low
income countries leads to a situation where others are
reluctant to start, and this makes more trial sponsors
also reluctant to start. The net result is a general pre-
sumption against FIH trials in LMICs.
This situation is beginning to change. This shift pre-
sents an opportunity to engage in a serious debate
about the basic logic of site selection for FIH trials.
Here, we are focused on FIH trials for diseases that pre-
sent important public health challenges for LMICs,
including the rapid emergence of a wide range of
chronic diseases [9]. In particular, we agree with the
ethical argument that trials should be responsive to the
health needs of host communities in the sense argued
by London and Kimmelman, that is, if they are “part of
a program of inquiry that will expand the capacity of
health-related social structures in the host community
to meet urgent health needs.”[10]. For example, it makes
little sense to perform FIH trials of malaria vaccines in
the United States today, as has happened recently with
the live attenuated sporozoite vaccine developed by
Sanaria [11], when malaria transmission stopped in the
US after World War II [12], but it continues to kill
about 1 million children a year in sub-Saharan Africa
[13].
There are also strong scientific and pragmatic argu-
ments. The diseases in question are most prevalent in
LMICs, where the epidemiology, health services, social
determinants of health, compliance patterns, co-morbid-
ities and the genetic make-up of the population also
have a bearing on the way in which the health products
will ultimately be used and hopefully achieve the desired
outcomes [14]. There is evidence that, mutations in
genes coding for drug-metabolizing enzymes may result
in drugs being metabolized differently in different popu-
lations [15], affecting the response and AEs to drugs
and vaccines [16]. The gastrointestinal microbiome may
also make a difference. Individuals with gastrointestinal
infections have been found to respond differently to
medical products, for example the live polio vaccine
[17]. Thus, testing drugs and vaccines in developed
countries, (whether in early or late phase trials), may
give misleading results.
An important consideration also relates to the need to
conduct both early and late phase clinical trials among
subjects who have the target disease. The ethical issues
here may need further reflection, but scientifically, there
are circumstances and arguments where it would be
beneficial to conduct such studies among the patient
population. For example, if there’s need to evaluate a
new product that cannot be assessed in healthy indivi-
duals for some reason, including ethical considerations,
then it may be necessary to recruit patients with the tar-
get diseases. In other cases, it may be difficult to extra-
polate the results from healthy individuals to a patient
population. In such instances, the results pertaining to a
new product maybe either over- or under-estimated
[18,19]. In these examples, it can be extrapolated to pro-
duct development for conditions that are most prevalent
in low income countries, and argued that it would be
reasonable for early stage trials to be conducted in these
countries where the relevant diseases are most prevalent
and it is possible to recruit patients.
The need to reconsider where FIH trials are done first
is becoming even more salient as LMICs push to expand
their involvement in all phases of drug development,
primarily as a source of revenue. More important,
though, is the fact that the pipeline of products for con-
ditions that occur predominantly in LMICs is improving
significantly [20]. Major philanthropies such as the Bill
& Melinda Gates Foundation fund discovery research
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in Global Health initiative [21], or indirectly through
many product-developing Public-Private Partnerships
(PPPs) [22], Similarly, large multinational pharmaceuti-
cal companies have begun, on their own or through
PPPs, to develop more health products for NTDs and
for diseases most prevalent in LMICs. Countries such as
India [23], China [24,25], and Brazil [26], now have their
own strong and growing pharmaceutical and vaccine
manufacturing industries- indeed half of childhood vac-
cines administered throughout the world by UNICEF
are made by one company in India [23].
An important underlying concern in this discussion is,
of course, the safety of human research volunteers and
the potential for exploitation of vulnerable populations
in LMICs (or indeed anywhere else in the world). By
definition, the risks in FIH trials, particularly for phase
0, are not known for sure: they could be non-existent,
low or, as in the TGN1412 case, high [2,3,22,27,28]. In
addition to posing risks to the participants, FIH trials
that do not completely take into account the design of,
and data from, preclinical trials may not provide the
necessary information to adequately evaluate the results
of FIH trials [5]. TGN1412 and other FIH trials in HIC
have shown us clearly that risks are inherent in these
trials and not unique to LMICs, and so we must be
careful not to impose more stringent standards on
LMICs (especially those which meet the necessary GCP
conditions) than we do on HIC.
Discussion
The necessary conditions exist
The United States Department of Health and Human
Services Office of the Inspector General (OIG) report of
June 2010 documents the increasing number of clinical
trials being conducted in LMIC [29,30], including a few
FIH trials [10,31]. UNAIDS also reports an increase in
various FIH HIV vaccine and microbicides trials in
Kenya, South Africa, Thailand and Uganda [32].
Furthermore, the U.S. National Institutes of Health
(NIH) clinical trials registry also reflects an increasing
number of phase I trials in LMICs most of the increase
having been registered in the most recent past 5-10
years [33] (Table 1).
Some commentators argue that that it is too risky to
conduct FIH trials at all in LMICs, since the necessary
conditions do not exist to ensure high technical stan-
dards and the safety of research participants [34,35]. We
disagree with this assessment and believe this presump-
tion unfairly treats all LMICs alike, even in the face of
growing evidence of rapid capacity development in
many LMICs. A number of initiatives to support clinical
trials, including FIH trials, in some LMICs, have had an
i m p a c t .I nI n d i a ,C h i n a ,a n dBrazil, for example, Good
Manufacturing Practice (GMP) and Good Clinical Prac-
tice (GCP) standards have improved dramatically [6].
These standards often bear a close relationship to the
quality of healthcare services more generally. There are
new hospitals/institutions, some of them in the private
sector, that are widely understood by clinical trial spe-
cialists in the West to have the same capacity as clinical
trial centers in the U.S to conduct FIH trials safely and
to high scientific standards [31]. How did these
improvements come about?
Having accepted that standards must be the same for
all countries, LMICs sought assistance in infrastructure
development and training that would facilitate imple-
mentation of a single set of internationally-harmonized
GCP standards- a goal that led the World Health Orga-
nization (WHO) to develop its 2002 GCP Handbook
and to embark on a series of educational/training pro-
grams in GCP in LMICs [36]. The United States Food
and Drug Administration (FDA) regulations for the
acceptance of data from non-U.S. studies are in fact
linked to these internationally harmonized GCP stan-
dards. Indeed, FDA now assists LMICs to build capacity
to review and inspect clinical research within their own
legal jurisdictions, as a way to improve the quality of
clinical trial data that might ultimately be submitted to
FDA [37]. Consequently, regulatory capacity is slowly
being enhanced not only in the emerging economies of
India and China, where FDA itself has set up offices
[38], but also in countries in sub-Saharan Africa [5,20].
Low and middle income countries cannot depend on
others for oversight of their clinical trials. The FDA, for
example, despite its good intentions, has been found to
lack the capacity “to effectively oversee clinical trials
conducted in LMICs” [1,6]. Particularly for the early
phase trials, the FDA has been reported to be unaware
that the trials are even going on [6], making it impossi-
ble for them to provide the necessary oversight. FDA’s
contribution should be in helping to build local capacity
for oversight or emulating the European Medical
Agency (EMEA), which has partnered with the WHO to
develop detailed guidelines intended to provide a
mechanism for licensing products of major public health
Table 1 Number of Phase 1 trials in low income countries
as registered by the NIH (2010)
Region Number of Phase I trials registered
Africa 103 (0 registered between 1995/2000)
Central America 84
East Asia (including Japan) 659
Middle East 267
South America 128 (0 registered between 1995/2000)
South Asia 94 (81 registered in India)
South East Asia 120
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licensed in the EU. Under this partnership, EMEA eval-
uates data on the quality, safety and efficacy of the pro-
duct contained in the application in collaboration with
the WHO, before issuing a scientific opinion regarding
the benefit-risk ratio of the product [39]. These initia-
tives have succeeded in ensuring that some institutions
in LMICs now have the capacity to conduct FIH trials
and to provide leadership and experience in the devel-
opment of rigorous and responsive home-grown clinical
trials programs.
Secondary benefits
Conducting FIH trials in low income countries in accor-
dance with international regulatory standards should
also drive capacity building for local ethical review, facil-
itate health care infrastructure development, increase
economic activity by encouraging research into more
innovative products, and reduce the culture of depen-
dency on developed countries [6,40,41]. As noted, there
are many late-phase clinical trials taking place in
LMICs, helped by initiatives to strengthen clinical trial
sites [42]. These include initiatives associated with the
European and Developing Country Clinical Trial Part-
nership (EDCTP) [43], the Malaria Clinical Trials Alli-
ance, the African Malaria Intervention Network
(AMANET] [44], the African Vaccine Regulatory Forum
(AVAREF), as well as initiatives to strengthen local
training institutions such as Uganda’s Mulago Hospital
HIV research centre of excellence, which helps provide
research training for the Sub-Saharan Africa region [45].
Many of these initiatives developed in response to the
proliferation of later phase clinical trials in LMICs, and
many researchers from LMICs believe the only way
their countries will improve their capacity to conduct
and regulate FIH trials is by doing so within their home
contexts [41].
We recognize the challenges of regulatory and other
deficiencies in those countries that have not already
caught up. We neither wish to trivialize the importance
of protecting human subjects, nor to argue that all
countries are now ready to do FIH trials. But we believe
that many countries now have the necessary capacity, or
could acquire it quickly, and that improving the neces-
sary conditions everywhere is good for research and
good for health. We acknowledge that clinical research
in low income countries has a mixed history and in
many instances has not enhanced equity. But this is true
as well in some high income countries. Hence, we
believe that the transition to conducting more FIH trials
in low income countries, while also calling attention to
deficiencies health systems and regulatory capacity,
could help to improve standards, particularly if taking
more ownership of trials and product development–as is
already occurring throughout the developing world
[46,47]–would allow for less reliance on developed
countries.
The way forward: a role for both the developed countries
and LMICs
We believe that trial sponsors, ethics review committees,
regulatory agencies and other stakeholders should work
together to develop explicit policies and programs that
w o u l dh e l pa d v a n c eL M I C s ’ ability to conduct high
quality clinical trials, including specific guidance and
capacity for FIH trials. Hence, in the absence of well
developed regulatory and science funding policies and
legal frameworks and clinical capacity, all these players
will have to get on the same page to develop a condu-
cive environment, emphasizing safety, clinical excellence
and scientific excellence.
There will increasingly be products meant specifically
for the developing world, manufactured in the develop-
ing world, that are of immense value locally, and that
will unlikely ever to be used in the developed world. A
change in mind-set is needed. LMIC regulatory agencies
must prioritize improvements of their own regulatory
regimes for these circumstances and begin to reduce
t h e i rr e l i a n c eo nt h eF D Ao rE M E Af o rp r i o ra p p r o v a l
of products before they have the courage to approve
them locally. In order to benefit from local experience
and be able to benefit more from capacity-building
assistance from donor communities, and to negotiate
more effectively, it would be wise to coordinate and har-
monize local regulatory approaches at a regional level.
In East Africa, for example, this could be through the
East African Community that links Tanzania, Kenya,
Uganda, Rwanda and Burundi. Indeed, there is already a
move to establish an East African Medicines and Food
Safety Commission [48].
Current thinking about research ethics review and
oversight in LMICs is shifting from an emphasis on
training and ethical principles to a deeper account of
the systems requirements to sustain effective review and
oversight [49]. This thinking might offer some direction
about what types of capacity-building will be required to
e n h a n c eF I Ht r i a l si nL M I C s[ 5 0 ] .T h ec a p a c i t yf o r
training ethicists and establishing ethics review boards,
which have increased significantly in the past decade,
could be strengthened even further through creative
programs such as the one developed by the NIH Fogarty
International Centre [50], which has spawned dozens of
local training programs around the world such as those
in India [51], Pakistan [52] and South Africa [53]. Such
initiatives could add FIH trial oversight to their curri-
cula. We expect that some of the most advanced emer-
ging economies will continue to lead, but the key will be
to harness the lessons from these countries in terms of
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tion, etc., so that other less well developed countries will
have a path to follow.
Summary
We have argued that while FIH studies have historically
n o tb e e nd o n ei nL M I C s ,t h es i t u a t i o ni nt h e s ec o u n -
tries has changed, and some of the reasons for not con-
ducting FIH in these countries, no longer hold true.
Hence, for products meant primarily for conditions that
are most prevalent in LMICs, more FIH trials should be
performed in LMICs, provided the protections are at
least equivalent to those provided in similar trials in
developing country clinical settings. While some coun-
tries in the developing world already have the capacity
to conduct FIH trials, to make this happen on a larger
scale will require enhanced capacity in regulatory over-
sight, health care infrastructure, clinical research infra-
structure, and ethics review in those countries where
these have not yet reached the necessary standards.
Since the advantages extend to both the developing and
developed worlds, we argue that all should work coop-
eratively to address those impediments that currently
discourage FIH trials from being done in the developing
world.
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